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Abstract
Objectives—To describe cases and estimate the annual incidence of tuberculosis in correctional 
facilities.
Methods—We analyzed 2002 to 2013 National Tuberculosis Surveillance System case reports to 
characterize individuals who were employed or incarcerated in correctional facilities at time they 
were diagnosed with tuberculosis. Incidence was estimated with Bureau of Justice Statistics 
denominators.
Results—Among 299 correctional employees with tuberculosis, 171 (57%) were US-born and 82 
(27%) were female. Among 5579 persons incarcerated at the time of their tuberculosis diagnosis, 
2520 (45%) were US-born and 495 (9%) were female. Median estimated annual tuberculosis 
incidence rates were 29 cases per 100 000 local jail inmates, 8 per 100 000 state prisoners, and 25 
per 100 000 federal prisoners. The foreign-born proportion of incarcerated men 18 to 64 years old 
increased steadily from 33% in 2002 to 56% in 2013. Between 2009 and 2013, tuberculosis 
screenings were reported as leading to 10% of diagnoses among correctional employees, 47% 
among female inmates, and 42% among male inmates.
Conclusions—Systematic screening and treatment of tuberculosis infection and disease among 
correctional employees and incarcerated individuals remain essential to tuberculosis prevention 
and control.
Mycobacterium tuberculosis transmission among correctional staff and inmates,1–4 with 
additional transmission to the community (including family and friends,5,6 children,6,7 and 
patients and staff of outside health care facilities8), has been well documented. However, 
quantifying the magnitude of the tuberculosis (TB) problem in jails and prisons is 
complicated by varying case-finding procedures across different settings, frequent inmate 
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transfers, unpredictable lengths of stay, high rates of recidivism, and challenges of 
maintaining continuity of care after release.9,10
Jails are facilities operated at the city or county level. Local jails typically confine 
individuals awaiting a court hearing, serving a sentence of less than 1 year, or anticipating 
transfer to prison. Prisons are longer-term facilities operated under the legal authority of 
state departments of corrections or the Federal Bureau of Prisons. Prisons typically hold 
individuals with sentences of more than 1 year. Whereas a local jail detention might range 
from hours to months, state imprisonment averages approximately 3 years and federal 
imprisonment approximately 5 years.11,12
US Immigration and Customs Enforcement (ICE), under the US Department of Homeland 
Security, has at least 30 000 people in custody at any given time while they are undergoing 
administrative immigration proceedings.13 Sixty-seven percent of ICE detainees are housed 
in local or state facilities under agreements with the operators of those facilities, and an 
additional 3% are in Federal Bureau of Prisons facilities. The remainder are in facilities 
owned (13%) or contracted (17%) by ICE. Individuals in ICE custody are detained for an 
average of 27 days.13
In a previous study, we estimated median annual TB incidence rates of 54 cases per 100 000 
local jail inmates, 17 per 100 000 state prisoners, and 30 per 100 000 federal prisoners 
during 1993 to 2003.14 The epidemiology of TB in the United States as a whole has shifted 
since that period such that the majority (66%) of new TB cases now occur among people 
born in other countries,15,16 leading to a greater emphasis on detecting and treating 
preexisting latent TB infections in foreign-born residents of the United States.17,18 If the 
epidemiology of TB in US jails and prisons has similarly shifted to involve more foreign-
born individuals, the choice of TB prevention and control strategies in correctional facilities 
might also need to be modified.10,19
In this national update to our previous study, we estimated annual TB incidence among 
inmates of local jails and state and federal prisons between 2002 and 2013. We describe 
characteristics of people who were incarcerated at the time their TB diagnostic evaluations 
began. We also describe TB cases that occurred during the same 12-year period among 
correctional employees.
METHODS
Our primary data source was the National Tuberculosis Surveillance System, through which 
the District of Columbia and the 50 US states report verified TB cases to the Centers for 
Disease Control and Prevention.15,20 We identified all individuals reported as employed in a 
correctional facility within the 12 months before their TB diagnosis and all people reported 
as incarcerated at the time their TB diagnostic evaluation began. In the National 
Tuberculosis Surveillance System, individuals are categorized as incarcerated only if they 
are considered a detainee or inmate when the TB diagnostic evaluation begins. Data on 
length of incarceration are unavailable; people are not reclassified if they become 
incarcerated during TB treatment. In the case of incarcerated individuals, but not employees, 
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the type of correctional facility is also reported. These types of facilities include local jails, 
state prisons, federal prisons, and a category labeled “other,” a classification that includes 
ICE detention facilities and other facilities.20
New surveillance variables were added in 2009, including whether the TB patient also has 
diabetes and the primary reason for the initial medical evaluation that led to the TB 
diagnosis. Choices for reason evaluated are mutually exclusive. The TB disease symptoms 
classification means that the person sought medical attention because of TB symptoms (i.e., 
symptoms were not found through a contact investigation or a routine screening). Routine 
TB screening means that the person had a positive test result for TB infection as part of 
nonoccupational screening focused on specific groups at higher risk for TB (i.e., targeted 
testing), which could include an intake assessment for residents of correctional facilities. 
Other reasons for the diagnosis (e.g., including an incidental finding from a chest radiograph 
or the results of a laboratory test ordered without suspicion of TB disease) are also 
options.20
Estimated Tuberculosis Incidence by Type of Facility
To estimate annual TB incidence among incarcerated individuals by type of correctional 
facility (i.e., local jail or state or federal prison), we used a methodology similar to that used 
to calculate TB incidence in the Centers for Disease Control and Prevention’s annual TB 
report15 after applying a steady-state assumption (i.e., stable daily average number of 
inmates). As with our previous report,14 we used data from the US Bureau of Justice 
Statistics for denominators in our incidence estimates. The bureau’s Annual Survey of Jails 
provided midyear numbers of individuals in local jails.21 Annual data collected from state 
departments of corrections and the Federal Bureau of Prisons provided year-end numbers of 
people in state and federal prisons.22 However, these data sources do not provide 
information on country of origin; therefore, we were not able to distinguish between US-and 
foreign-born inmates in our incidence estimates.
Case Characteristics and Analysis
More than 90% of the incarcerated individuals included in our analysis were male, which is 
consistent with the preponderance of men aged 18 to 64 years in the incarcerated population 
in the United States.21,22 Therefore, here we focus on men in this age group and provide 
only a brief description of results among incarcerated women, juvenile men, and older men 
with TB. In our analyses, we examined clinical characteristics of TB patients (e.g., previous 
TB diagnosis, disease site, and drug resistance). Demographic characteristics assessed 
included country of origin, self-reported race/ethnicity, and available social risk factors (i.e., 
homelessness and substance use during the 12 months before TB diagnosis). Complete data 
were available for more than 90% for all examined variables with the exception of substance 
use among foreign-born individuals and HIV co-infection.
Because the epidemiology of TB differs markedly between US- and foreign-born 
individuals,15,16,18,23 we stratified these 2 groups when comparing characteristics between 
incarcerated and nonincarcerated men aged 18 to 64 years during 2002 to 2013. Using 
logistic regression to estimate adjusted effects of age group, race/ethnicity, HIV infection, 
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homelessness, and substance use, we modeled the odds of being incarcerated at the time of 
TB diagnosis. Prevalence odds ratios and 99% confidence intervals were calculated to 
compare differences in magnitudes of associations.
We noted marked differences by type of correctional facility in estimated TB incidence, 
foreign-born proportions, and reasons for TB evaluation. Therefore, we further partitioned 
the men in these types of facilities as 3 distinct populations to allow additional descriptions. 
We used SAS version 9.3 (SAS Institute Inc, Cary, NC) in conducting all of our analyses.
RESULTS
During 2002 through 2013, 35 US states reported 299 TB cases among people employed in 
correctional facilities, and every state other than Vermont and Wyoming reported at least 1 
TB case in a correctional facility inmate (n = 5579 cases).
Correctional Employees With Tuberculosis
The median age of correctional employees with TB was 44 years (range = 20–82); 171 
(57%) of these 299 employees were US-born, and 82 (27%) were women. Eleven (4%) were 
either dead at TB diagnosis or died during treatment; their median age was 50 years (range = 
33–71) at time of death.
Eighty-one (96%) of the 84 correctional employees with TB during 2009 through 2013 had 
information reported about the circumstances leading to the TB diagnosis: 40 (49%) self-
presented for medical attention because of TB disease symptoms, 25 (31%) were reported as 
having TB diagnosed incidentally, 9 (11%) were identified through a TB screening or other 
occupational testing, and 7 (9%) were identified through contact investigations after a known 
TB exposure.
Incidence by Location and Type of Facility
Four large states (California, Texas, Florida, and New York) reported the majority (57%) of 
the 5579 TB cases among correctional facilities (n = 3190). In Arizona and Georgia, more 
than 200 cases each occurred in detention or correctional facilities. Nearly half of the cases 
reported (n = 2577) were among foreign-born individuals; the most frequent countries of 
origin were Mexico (n = 1489), Honduras (n = 289), Guatemala (n = 180), and El Salvador 
(n = 130). Approximately half (n = 2674, or 48%) of all cases nationally occurred in local 
jails, 1234 (22%) occurred in state prisons, and 594 (11%) occurred in federal prisons. 
Another 915 (16%) were classified as occurring in the “other facility” category, which 
would include ICE detention facilities.20 Data on facility type were missing or unknown for 
the remaining 162 cases (3%).
The estimated annual TB incidence during 2002 to 2013 was lower for state prisoners (3–10 
cases per 100 000 inmates; median = 8) than for federal prisoners (18–36 cases per 100 000; 
median = 25) and local jail inmates (24–37 cases per 100 000; median = 29; Table 1). 
Meanwhile, the overall national TB incidence decreased from 5.2 cases per 100 000 
population in 2002 to 3.0 per 100 000 in 2013.15
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Female Inmates With Tuberculosis
Of the 5579 individuals incarcerated at the time of TB diagnosis during 2009 through 2013, 
495 (9%) were female. Among these female inmates, 369 (75%) were US-born, 9 (2%) were 
younger than 18 years, and 8 (2%) were older than 64 years. The 2 most common types of 
correctional facilities were local jails (n = 268, or 54%) and state prisons (n = 103, or 21%). 
Among the 154 (31%) female inmates with information about the circumstances leading to 
their TB diagnosis, the most common means of diagnosis was a routine TB screening (47% 
of diagnoses were the result of targeted testing).
Juvenile and Older Men With Tuberculosis
Of the 5084 male inmates with TB, 40 (< 1%) were younger than 18 years and 84 (2%) were 
older than 64 years. After exclusion of an additional 26 men with TB whose age or country 
of birth was unknown, data for 4934 inmates remained for subsequent analysis.
Demographic Trends Among Incarcerated Adult Men
Among the 4934 men aged 18 to 64 years with TB diagnosed during incarceration, the 
proportion who were foreign-born was 33% in 2002 and then steadily increased, surpassing 
the US-born proportion in 2008 and reaching 56% in 2013 (Figure 1). Foreign-born 
incarcerated men with TB tended to be younger (median = 33 years) than US-born 
incarcerated men with the disease (median = 41 years).
Among the 4934 men, 2087 (42%) were foreign-born Hispanics, 1373 (28%) were US-born 
non-Hispanic Blacks, 594 (12%) were US-born non-Hispanic Whites, and 459 (9%) were 
US-born Hispanics. Among the 2414 foreign-born men, 2073 (86%) had a reported US 
arrival date; 1083 (52%) of these men had arrived within a year of their diagnosis.
Culture confirmation of M. tuberculosis was available for 79% of the inmates with TB 
diagnoses; also, in 97% of these cases, drug susceptibility results were available for 
isoniazid and rifampin. Approximately 1% of the men demonstrated resistance to isoniazid 
and rifampin (i.e., they exhibited multidrug-resistant TB).
Among the male inmates during 2009 through 2013 for whom diabetes status and evaluation 
reason were reported, 4% had diabetes (lower than the overall national prevalence of 15% 
among TB patients15), and 42% of TB diagnoses were reported as being the result of routine 
TB screening procedures (i.e., targeted testing). Adjusted analyses showed that previous TB 
and substance use were associated with incarceration at the time of TB diagnosis (Table 2).
Differences by Facility Type Among Incarcerated Men
During 2002 through 2013, 2357 (48%) of the 4934 male inmates aged 18 to 64 years with 
TB diagnosed during incarceration were housed in local jails. A total of 359 (27%) of the 
1335 US-born men and 151 (15%) of the 1022 foreign-born men with TB diagnosed while 
in a local jail had been homeless during the preceding year. Among the 877 foreign-born jail 
inmates with a reported date of arrival in the United States, 320 (36%) had entered the 
country within a year before their diagnosis.
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Of the 4934 male inmates with TB, 1079 (22%) were in state prisons. The majority of these 
inmates (86%) were US-born. Fewer than 7% of state prisoners with TB had experienced 
homelessness in the past year.
A smaller number of inmates (n = 554, or 11%) were housed in federal prisons. The 
majority (76%) were foreign-born. Among the 363 foreign-born federal prisoners with a 
reported US arrival date, 206 (57%) had arrived within a year before their diagnosis.
DISCUSSION
Although TB incidence nationally15 and in jails and prisons14 declined steadily between 
1993 and 2013, incarcerated populations continue to experience TB at a substantially higher 
incidence than in the general population. Local jails remain the facilities with both the 
largest number and highest incidence of TB cases. Although federal facilities still report the 
fewest TB cases, the estimated incidence in those facilities was similar to that in local jails 
owing to their relatively smaller populations. State prisons have sustained a steady decline in 
TB incidence, now approaching that of the overall US population; however, they still 
contribute a substantial number of TB cases among incarcerated individuals in the United 
States.
The preponderance of TB patients in state prisons, where TB incidence was lowest, are US-
born. Although length of incarceration was not a surveillance variable, the 7% prevalence of 
recent homelessness among state prisoners might indicate that their incarcerations are more 
longstanding at the time of their TB diagnosis. A longer history of incarceration might be 
associated with previous access to TB control efforts such as treatment of latent TB 
infection.10,17,24
The higher TB incidence in local jails and federal prisons appears to correspond to higher 
proportions of foreign-born individuals receiving TB diagnoses during incarceration, often 
within months of their arrival in the United States. Recent arrival in the United States is well 
established as a risk factor for TB disease.18,23 Our findings also demonstrate successful TB 
case detection procedures for recently arrived foreign-born inmates in local jails and federal 
prisons, which would signal progress since the early 1990s, when reports described 
transmission resulting from TB cases that were not recognized during intake.5,24–26
Limitations
Our analysis is subject to certain limitations. For example, TB associated with recent arrival 
was likely underascertained among foreign-born individuals because the United States 
includes TB cases in national surveillance counts only if a person with a verified TB 
diagnosis has been or plans to remain in the United States for at least 90 days.20 Because the 
National Tuberculosis Surveillance System currently defines incarceration status only on the 
basis of when the TB diagnostic evaluation began,20 we have underestimated the proportion 
of TB cases associated with incarceration. Conversely, successful active case finding during 
routine intake procedures might help detect TB cases sooner than they would have been 
detected in the general community.
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Because we used numbers from the US Bureau of Justice Statistics21,22 as the denominators 
for our annual incidence estimates, we had to assume that the bureau’s data on midyear 
numbers of individuals in local jails and year-end numbers of individuals in state and federal 
prisons were valid approximations of the total number of person-years represented by each 
of those 3 populations for the calendar year in question. However, owing to rapid inmate 
turnover, the cumulative number of people who undergo TB screenings upon intake into a 
correctional facility each year is far higher than the average daily number of inmates would 
imply. Finally, surveillance data for certain variables were missing, particularly in the case 
of foreign-born incarcerated men (e.g., data on substance use and HIV status).
Conclusions
In addition to detecting and treating active TB disease at intake, correctional facilities offer a 
venue for identifying individuals with TB infection and offering them treatment, if indicated, 
to prevent later progression to active TB.24 Although the standard 9-month isoniazid and 4-
month rifampin regimens for treating latent TB infection are still options,17 the shorter 
course regimen recommended in 2011 (i.e., isoniazid and rifapentine administered once 
weekly for 12 weeks via directly observed therapy)27 can be a particularly favorable option 
to implement on a larger scale in correctional facilities. This 12-dose isoniazid–rifapentine 
regimen, which quadrupled treatment completion in an urban jail after its introduction in 
2012,28 is now the standard of care for the Federal Bureau of Prisons29 and is less 
hepatotoxic and more cost-effective than 9 months of daily isoniazid for latent TB 
infection.30,31
After baseline testing for infection with M. tuberculosis, employees of correctional facilities 
that house substantial numbers of inmates with TB risk factors (e.g., HIV, foreign country of 
birth) should receive TB screening at least annually.10 When institutional TB prevention and 
care procedures are ineffective, M. tuberculosis transmission to correctional employees is an 
occupational health concern.10 A 1990s TB outbreak in a jail in Tennessee included 5 
correctional officers.2 In 2004 in Florida, 5 TB cases were identified among correctional 
staff (1 secretary and 4 officers).3 In 2009 in Texas, a missed TB diagnosis led to 3 TB cases 
among staff guarding a local jail inmate while he was hospitalized.8 Although correctional 
employees and health care providers serving incarcerated populations are at increased risk of 
TB exposure,1–3,8 our analysis suggests that TB case ascertainment among correctional 
employees was rarely attributable to employment-related TB testing or contact investigation 
activities.
Given the typical rapid inmate turnover within jails and frequent transfers among 
prisons,10,32 M. tuberculosis transmission beyond jails and prisons into the surrounding 
community and even more distant areas can occur when prompt and effective TB screening 
procedures, followed by effective treatment of both TB disease and infection, are 
lacking.5–8,24,32 During the 1990s, one county in New York diagnosed 40 TB cases among 
current or former inmates, 1 case in a correctional officer, and 8 cases among individuals 
exposed in the community.5 In more recent TB outbreaks that have spread from the state 
prison system to communities in Arkansas4 and Tennessee,6 inmates either had been 
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released before treatment of latent TB infection could be completed4 or were known to have 
been recently infected but did not receive treatment.6
Public Health Implications
Prevention and cure of TB among incarcerated individuals require more focused attention in 
the United States, especially because the epidemiology of TB in jails and prisons is shifting 
to involve more people recently arriving from countries with a higher prevalence of TB, 
which lends itself to a greater emphasis within correctional facilities, as in the general 
community, on detecting and treating preexisting TB infection.17,18 Systematic screening 
and treatment of both TB disease and TB infection among inmates and correctional 
employees can benefit those individuals as well as the broader community.
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FIGURE 1. 
Men Aged 18–64 Years Who Were Incarcerated at the Time of Their Tuberculosis 
Diagnosis, by Birth Origin: United States, 2002–2013
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